Access DB# 86782

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Mike Meller Examiner #: 69404 Date 2/13/03
Art Unit: 1654 Phone Number 30 8-4230 Serial Number: 10/026,408
Mail Box and Bldg/Room Location: CM1 10A03 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Cytostatic - integrin conjugates having specificity...

Inventors (please provide full names): Lerchen Hans-Georg; Baumgarten, Jörg; Lockhoff Oswald; Albers Markus; Schoop Andreas

Earliest Priority Filing Date: 12/27/2000

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please Search Example 2
on all relevant databases.
i.e. CAS, Biosis, medline, Registry
etc.

Point of Contact:
Beverly Shears
Technical Info. Specialist
CM1 1E05 Tel: 308-4994

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Beverly 84994	NA Sequence (#)	STN ✓
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#)	Questel/Orbit
Date Searcher Picked Up:	Bibliographic	Dr.Link
Date Completed: 02-14-03	Litigation	Lexis/Nexis
Searcher Prep & Review Time: 12	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time: 10	Other	Other (specify)

PTO-1590 (8-01)

283613-52-5P 283613-53-6P 283613-54-7P 283613-55-8P
283613-56-9P 283613-57-0P 283613-58-1P 283613-59-2P
283613-60-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(prepn. of .beta.-phenylalanine derivs. as integrin antagonists)

L8 ANSWER 4 OF 5 MARPAT COPYRIGHT 2003 ACS
(ALL HITs ARE ITERATION INCOMPLETES)
ACCESSION NUMBER: 133:89443 MARPAT
TITLE: Quinolinecarboxamides as antiviral agents, especially against viruses of the herpes family
INVENTOR(S): Turner, Steven Ronald; Strohbach, Joseph Walter; Thaisrivongs, Suvit; Vaillancourt, Valerie A.; Schnute, Mark E.; Tucker, John Alan
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 219 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040561	A1	20000713	WO 1999-US27960	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248739	B1	20010619	US 1999-466712	19991217
EP 1140850	A1	20011010	EP 1999-967145	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534416	T2	20021015	JP 2000-592270	19991222
NO 2001003383	A	20010907	NO 2001-3383	20010706
PRIORITY APPLN. INFO.:			US 1999-115301P	19990108
			US 1999-140610P	19990623
			WO 1999-US27960	19991222

GI



AB The invention provides quinolinecarboxamides I (X = O, S; W = R2, etc., where R1-R6 = a wide variety of defined groups, with 125 examples), e.g., hydroxypropynyl deriv. II, and their pharmaceutically acceptable salts which are useful as antiviral agents, in particular, as agents against viruses of the herpes family. Activities of the compds. against HCMV, HSV, and VZV polymerase are presented. Pharmaceutical compns. comprising compds. I are claimed (no examples).

IC ICM C07D215-16
ICS C07D215-18; C07D215-22; C07D215-36; C07D215-38; C07D215-58; C07D215-233; A61K031-47; A61P031-12

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

ST quinolinecarboxamide prepn antiviral agent; herpes virus quinolinecarboxamide antiviral agent

IT Antiviral agents
(quinolinecarboxamides as antiviral agents)

IT Human herpesvirus 4
(quinolinecarboxamides for treatment of Epstein-Barr virus)

IT Cytomegalovirus
(quinolinecarboxamides for treatment of cytomegalovirus)

IT Human herpesvirus 1
(quinolinecarboxamides for treatment of herpes simplex virus type 1)

IT Human herpesvirus 2
(quinolinecarboxamides for treatment of herpes simplex virus type 2)

IT Human herpesvirus 6
(quinolinecarboxamides for treatment of human herpes virus type 6)

IT Human herpesvirus 7
(quinolinecarboxamides for treatment of human herpes virus type 7)

IT Human herpesvirus
(quinolinecarboxamides for treatment of human herpes viruses)

IT Human herpesvirus 3

(quinolinecarboxamides for treatment of varicella zoster virus)

IT Amides, preparation
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinolinecarboxamides; prepn. of quinolinecarboxamides as antiviral agents)

IT 29943-42-8, Tetrahydro-4H-pyran-4-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(conversion to oxazepanone and for prepn. of quinolinecarboxamide derivs.)

IT 1072-72-6, Tetrahydrothiopyran-4-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(conversion to thiazepane)

IT 77771-02-9, 3-Bromo-4-fluorobenzaldehyde
RL: RCT (Reactant); RACT (Reactant or reagent)
(for benzylation of morpholine)

IT 57-14-7, 1,1-Dimethylhydrazine 75-26-3, 2-Bromopropane 87-13-8, Diethyl ethoxymethylenemalonate 100-11-8, 4-Nitrobenzyl bromide 102-71-6, reactions 104-63-2, N-Benzylethanolamine 104-86-9, 4-Chlorobenzylamine 106-93-4, 1,2-Dibromoethane 107-08-4, 1-Iodopropane 107-19-7, Propargyl alcohol 110-65-6, 1,4-Butynediol 110-73-6 110-77-0, Ethyl 2-hydroxyethyl sulfide 110-91-8, Morpholine, reactions 111-46-6, reactions 111-90-0, 2-Ethoxy-(2-ethoxy)ethanol 112-35-6, Triethyleneglycol monomethyl ether 140-75-0, 4-Fluorobenzylamine 350-46-9, 1-Fluoro-4-nitrobenzene 352-34-1, 4-Fluoroiodobenzene 505-10-2, 3-Methylthiopropanol 513-48-4, 2-Iodobutane 540-37-4, 4-Iodoaniline 615-43-0, 2-Iodoaniline 622-08-2, 2-Benzyloxyethanol 628-89-7, 2-(2-Chloroethoxy)ethanol 699-12-7, 2-Hydroxyethyl phenyl sulfide 881-95-8, dl-Metanephrine hydrochloride 927-74-2, 3-Butyn-1-ol 1069-72-3 1445-73-4, N-Methyl-4-piperidone 1479-24-9, Ethyl 3-(2-fluorophenyl)-3-oxopropanoate 2008-75-5, 1-(2-Chloroethyl)piperidine hydrochloride 2213-43-6, 1-Aminopiperidine 2373-51-5, Chloromethyl methyl sulfide 3647-69-6, N-(2-Chloroethyl)morpholine hydrochloride 3970-21-6, 2-Methoxyethoxymethyl chloride 4261-68-1, 2-(Diisopropylamino)ethyl chloride hydrochloride 4319-49-7, 4-Aminomorpholine 4584-46-7, Dimethylaminoethyl chloride hydrochloride 5188-07-8, Sodium thiomethoxide 5292-43-3, tert-Butyl bromoacetate 5407-04-5, 3-Dimethylaminopropyl chloride hydrochloride 5466-88-6, (2H)1,4-Benzoxazin-3(4H)-one 5472-49-1, N-(3-Chloropropyl)piperidine hydrochloride 6148-64-7, Potassium ethyl malonate 6542-54-7 6589-55-5, .alpha.-(Methylaminomethyl)benzyl alcohol 6928-85-4, 1-Amino-4-methylpiperazine 6972-79-8, 1,3-Dibenzyloxy-2-propanol 7205-90-5, Chloromethyl 4-chlorophenyl sulfide 7205-91-6, Chloromethyl phenyl sulfide 7250-67-1, 1-(2-Chloroethyl)pyrrolidine hydrochloride 10595-09-2, 3,3'-Thiodipropanol 16589-24-5, Synephrine 16596-41-1, 1-Aminopyrrolidine 17201-43-3, 4-(Bromomethyl)benzonitrile 18621-18-6, 3-Azetidinol hydrochloride 21151-56-4, .alpha.,4-Dichloroanisole 26177-44-6, 4-Bromobenzylamine hydrochloride 27374-25-0, [(1-Ethoxycyclopropyl)oxy]trimethylsilane 29632-74-4, 2-Fluoro-4-iodoaniline 31560-06-2 33821-94-2, 2-(3-Bromopropoxy)tetrahydro-2H-pyran 50586-80-6, 2-(2-Methoxyethoxy)ethyl p-toluenesulfonate 54288-69-6, 2-Chloromethyl-1-methylpyrrolidine hydrochloride 58305-05-8 72748-99-3, (R)-1-Amino-2-(methoxymethyl)pyrrolidine 79099-07-3,

1-(tert-Butoxycarbonyl)-4-piperidone 84466-87-5,
4-(Azidomethyl)benzonitrile 117924-33-1 121838-84-4
132091-42-0 281652-58-2, 2-Chloro-5-iodobenzoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(for prepn. of quinolinecarboxamide derivs.)

IT 2767-70-6P, 4-Nitrobenzyltriphenylphosphonium bromide 5638-60-8P
6425-46-3P, 4-(4-Nitrobenzyl)morpholine 10406-25-4P,
4-(Aminomethyl)benzonitrile 21987-29-1P, 4,4-Difluoropiperidine
51013-67-3P, 4-(4-Aminobenzyl)morpholine 101184-85-4P
124700-41-0P, 2-Fluoro-5-iodobenzoic acid 281651-96-5P,
N-Cyclopropyl-4-iodoaniline 281652-00-4P 281652-01-5P
281652-05-9P 281652-10-6P, tert-Butyl 4,4-difluoro-1-
piperidinecarboxylate 281652-11-7P, 4-Fluoro-1,2,3,6-
tetrahydropyridine hydrochloride 281652-25-3P,
4-(3-Bromo-4-fluorobenzyl)morpholine 281652-26-4P 281652-27-5P
281652-40-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(for prepn. of quinolinecarboxamide derivs.)

IT 49713-42-0P, Ethyl 4-hydroxy-8-iodo-3-quinolinecarboxylate
58287-31-3P 103318-52-1P 188752-88-7P 228725-37-9P
228725-72-2P 228725-85-7P 228726-33-8P 228726-41-8P
228726-42-9P 228726-59-8P 228726-66-7P 228726-92-9P
228726-93-0P 228728-08-3P 228728-23-2P, Ethyl
4-hydroxy-6-iodoquinoline-3-carboxylate 228728-41-4P
228728-42-5P 281651-90-9P 281651-91-0P 281651-92-1P
281651-93-2P 281651-94-3P 281651-95-4P 281651-97-6P
281651-98-7P 281651-99-8P 281652-02-6P 281652-03-7P
281652-04-8P 281652-06-0P 281652-07-1P 281652-08-2P
281652-09-3P 281652-12-8P 281652-13-9P 281652-14-0P
281652-15-1P 281652-21-9P 281652-22-0P, 4-(4-
Nitrobenzylidene)tetrahydro-2H-pyran 281652-23-1P 281652-24-2P
281652-28-6P 281652-29-7P 281652-30-0P 281652-31-1P
281652-32-2P 281652-33-3P 281652-34-4P 281652-35-5P
281652-36-6P 281652-37-7P 281652-38-8P 281652-39-9P
281652-41-3P 281652-42-4P 281652-44-6P 281652-45-7P
281652-46-8P 281652-47-9P 281652-48-0P 281652-49-1P
281652-50-4P 281652-51-5P 281652-52-6P 281652-53-7P
281652-54-8P 281652-55-9P 281652-56-0P 281652-57-1P
281652-59-3P 281652-60-6P 281652-61-7P 281652-62-8P
281652-63-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(intermediate, for prepn. of quinolinecarboxamide derivs. as
antiviral agents)

IT 281652-16-2P 281652-17-3P 281652-18-4P 281652-19-5P
281652-20-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(intermediate, for prepn. of quinolinethiocarboxamide derivs. as
antiviral agents)

IT 10341-26-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(prepn. and hydride redn. to oxazepane)

IT 2896-98-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)

(prepn. and hydride redn. to thiazepane)

IT 281650-73-5P 281650-90-6P 281650-91-7P 281650-93-9P
281650-96-2P 281650-97-3P 281651-04-5P 281651-07-8P
281651-22-7P 281651-25-0P 281651-26-1P 281651-31-8P
281651-38-5P 281651-40-9P 281651-41-0P 281651-48-7P
281651-65-8P 281651-70-5P 281651-76-1P 281651-82-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of quinolinecarboxamides as antiviral agents, esp. against herpes virus)

IT 281650-66-6P 281650-67-7P 281650-68-8P 281650-69-9P
281650-70-2P 281650-71-3P 281650-72-4P 281650-74-6P
281650-75-7P 281650-76-8P 281650-77-9P 281650-78-0P
281650-79-1P 281650-80-4P 281650-81-5P 281650-82-6P
281650-83-7P 281650-84-8P 281650-85-9P 281650-86-0P
281650-87-1P 281650-88-2P 281650-89-3P 281650-92-8P
281650-94-0P 281650-95-1P 281650-98-4P 281650-99-5P
281651-01-2P 281651-02-3P 281651-08-9P 281651-09-0P
281651-10-3P 281651-11-4P 281651-12-5P 281651-13-6P
281651-14-7P 281651-15-8P 281651-16-9P 281651-17-0P
281651-18-1P 281651-19-2P 281651-20-5P 281651-21-6P
281651-23-8P 281651-24-9P 281651-27-2P 281651-28-3P
281651-29-4P 281651-30-7P 281651-32-9P 281651-33-0P
281651-34-1P 281651-35-2P 281651-36-3P 281651-37-4P 281651-39-6P 281651-42-1P 281651-43-2P 281651-44-3P 281651-45-4P
281651-46-5P 281651-47-6P 281651-49-8P 281651-50-1P
281651-51-2P 281651-52-3P 281651-53-4P 281651-54-5P
281651-55-6P 281651-57-8P 281651-58-9P 281651-59-0P
281651-60-3P 281651-61-4P 281651-62-5P 281651-63-6P
281651-64-7P 281651-66-9P 281651-67-0P 281651-68-1P
281651-69-2P 281651-71-6P 281651-72-7P 281651-73-8P
281651-74-9P 281651-75-0P 281651-77-2P 281651-78-3P
281651-79-4P 281651-80-7P 281651-81-8P 281651-83-0P
281651-84-1P 281651-85-2P 281651-86-3P 281651-87-4P
281651-88-5P 281651-89-6P 281652-43-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolinecarboxamides as antiviral agents, esp. against herpes virus)

IT 281651-00-1P 281651-03-4P 281651-05-6P 281651-06-7P
281651-56-7P 281652-64-0P 281652-65-1P 281652-66-2P
281652-67-3P 281652-68-4P 281652-69-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolinecarboxamides as antiviral agents, esp. against herpes virus)

IT 603-35-0, Triphenylphosphine, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(quaternization with nitrobenzyl bromide)

IT 78191-00-1, N-Methyl-N-methoxyacetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with bromofluorobenzylmorpholine)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN

THE RE FORMAT

L8 ANSWER 5 OF 5 MARPAT COPYRIGHT 2003 ACS
(ALL HITs ARE ITERATION INCOMPLETES)
ACCESSION NUMBER: 129:95491 MARPAT
TITLE: Preparation of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivatives as Na+/H+ exchanger inhibitors
INVENTOR(S): Okazaki, Toshio; Kikuchi, Kazumi; Sugasawa, Keizo; Kaku, Hidetaka; Takanashi, Masahiro
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Merck Patent G.m.b.H.; Kikuchi, Kazumi; Sugasawa, Keizo; Kaku, Hidetaka; Takanashi, Masahiro
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827061	A1	19980625	WO 1997-JP4605	19971215
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9711102	A	19980813	ZA 1997-11102	19971210
AU 9854119	A1	19980715	AU 1998-54119	19971215
PRIORITY APPLN. INFO.:			JP 1996-335638	19961216
			WO 1997-JP4605	19971215

GI



I





II

AB N-[(Substituted five-membered heteroaryl)carbonyl]guanidine derivs. represented by general formula (I) or pharmacol. acceptable salts thereof [wherein the five-membered heteroaryl ring represents Q or Q1 (wherein X1 represents oxygen, sulfur, or NR3; and X2 represents nitrogen or CR4); R1 represents optionally substituted aryl or optionally substituted five- or six-membered monocyclic heteroaryl; R2 represents hydrogen, halogeno, optionally halogen-substituted lower alkyl, lower alkoxy, lower alkylthio, or optionally protected amino, provided that when the R1-substituted five-membered heteroaryl ring is Q2, R2 is neither hydrogen nor ethoxy; and R3 and R4 each represents hydrogen or optionally halogen-substituted lower alkyl] are prepd. They are useful as a drug, esp. an Na+/H+ exchanger inhibitor, for the prevention, treatment, or diagnosis of various diseases in which an Na+/H+ exchanger participates, such as hypertension, arrhythmia, angina pectoris, myocardial infarct, organ damages caused by ischemia or ischemic reperfusion, cell proliferative diseases (e.g. arteriosclerosis and cancer), and disorders caused by high blood sugar (e.g. complications of diabetes). Thus, imidazole was treated with NaH in DMF at room temp. for 30 min and then stirred with Et 2-[3-(2-bromoethoxy)phenyl]-4-methylthiazole-5-carboxylate at 70.degree. for 3 h followed by heating with guanidine hydrochloride in the presence of NaH at 80.degree. for 3 h to give the title compd., [(imidazolylmethoxy)phenyl]thiazolecarbonylguanidine deriv. (II). The tile compds. I in vitro inhibited Na+/H+ exchanger with Ki of from 10-6 to 10-8.

IC ICM C07D231-14
ICS C07D231-38; C07D233-90; C07D249-10; C07D263-34; C07D277-24; C07D277-34; C07D453-02; A61K031-415; A61K031-42

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST imidazolylmethoxyphenylthiazolecarbonylguanidine prepn proton sodium exchanger inhibitor; thiazolecarbonylguanidine prepn proton sodium exchanger inhibitor; hypertension treatment oxazolecarbonylguanidine; arrhythmia treatment triazolecarbonylguanidine; angina pectoris treatment triazolecarbonylguanidine; myocardial infarct treatment

imidazolecarbonylguanidine; organ damage ischemia ischemic reperfusion; cell proliferative disease arteriosclerosis cancer; disorder high blood sugar complication diabetes; heteroarylcarbonylguanidine prepn antihypertensive; pyrazolecarbonylguanidine prepn antiarteriosclerotic

IT Heart, disease
(angina pectoris; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Heart, disease
(arrhythmia; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Diabetes mellitus
(complications; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Cell proliferation
(disease; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Transport proteins
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(hydrogen ion-sodium-exchanging; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Organ, animal
Organ, animal
(injury; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Reperfusion
(ischemic, organ damages caused by; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Ischemia
(organ damages caused by; prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT Antiarteriosclerotics
Antidiabetic agents
Antihypertensives
Antitumor agents
(prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT 209537-03-1P 209537-04-2P 209537-05-3P 209537-06-4P
209537-07-5P 209537-08-6P 209537-09-7P 209537-11-1P
209537-13-3P 209537-14-4P 209537-15-5P 209537-16-6P
209537-17-7P 209537-18-8P 209537-21-3P 209537-22-4P
209537-23-5P 209537-26-8P 209537-27-9P 209537-28-0P
209537-29-1P 209537-30-4P 209537-31-5P 209537-32-6P
209537-34-8P 209537-36-0P 209537-38-2P 209537-40-6P
209537-43-9P 209537-45-1P 209537-47-3P 209537-49-5P
209537-51-9P 209537-53-1P 209537-55-3P 209537-57-5P
209537-60-0P 209537-62-2P 209537-64-4P 209537-66-6P

209537-67-7P 209537-69-9P 209537-72-4P 209537-74-6P
209537-76-8P 209537-79-1P 209537-80-4P 209537-81-5P
209537-82-6P 209537-84-8P 209537-87-1P 209537-89-3P
209537-91-7P 209537-93-9P 209537-96-2P 209537-98-4P
209537-99-5P 209538-01-2P 209538-04-5P 209538-06-7P
209538-08-9P 209538-10-3P 209538-12-5P 209538-13-6P
209538-14-7P 209538-15-8P 209538-17-0P 209538-20-5P
209538-22-7P 209538-23-8P 209538-25-0P 209538-28-3P
209538-30-7P 209538-32-9P 209538-34-1P 209538-37-4P
209538-39-6P 209538-41-0P 209538-42-1P 209538-43-2P
209538-44-3P 209538-46-5P 209538-47-6P 209538-48-7P
209538-50-1P 209538-52-3P 209538-53-4P 209538-55-6P
209538-57-8P 209538-58-9P 209538-60-3P 209538-61-4P
209538-63-6P 209538-65-8P 209538-66-9P 209538-69-2P
209538-70-5P 209538-71-6P 209538-73-8P 209538-75-0P
209538-78-3P 209538-80-7P 209540-12-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT 50-01-1, Guanidine hydrochloride 99-09-2, 3-Nitroaniline 100-39-0, Benzyl bromide 109-54-6, 3-(Dimethylamino)propyl chloride 109-64-8, 1,3-Dibromopropane 110-52-1, 1,4-Dibromobutane 118-90-1, o-Methylbenzoic acid 124-40-3, Dimethylamine, reactions 141-97-9, Ethyl acetoacetate 288-32-4, Imidazole, reactions 363-58-6, Ethyl 2-chloro-4,4,4-trifluoroacetoacetate 459-57-4, p-Fluorobenzaldehyde 501-53-1, Benzyl chloroformate 536-90-3, 3-Methoxyaniline 609-15-4, Ethyl 2-chloroacetoacetate 625-36-5, 3-Chloropropionyl chloride 873-62-1, m-Cyanophenol 4637-24-5 5407-04-5 6214-65-9, 5-Acetyluracil 7333-63-3, (4-Bromobutyl)triphenylphosphonium bromide 18355-96-9, 3-(Dimethylamino)propyltriphenylphosphonium bromide 20691-89-8, 1-Methylpiperidine-4-methanol 24252-37-7 24964-64-5, 3-Cyanobenzaldehyde 26628-22-8, Sodium azide 39232-91-2, 3-Methoxyphenylhydrazine hydrochloride 51516-96-2, 3-Nitrophenylhydrazine hydrochloride 63888-94-8 209540-05-6 209540-06-7 209540-08-9 209540-09-0 209540-10-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

IT 20954-27-2P 24723-35-1P 61147-43-1P, 3-(Benzyloxy)benzonitrile 90208-22-3P 209538-81-8P 209538-82-9P 209538-83-0P
209538-84-1P 209538-86-3P 209538-87-4P 209538-88-5P
209538-89-6P 209538-91-0P 209538-92-1P 209538-93-2P
209538-94-3P 209538-96-5P 209538-97-6P 209538-98-7P
209538-99-8P 209539-00-4P 209539-02-6P 209539-03-7P
209539-04-8P 209539-05-9P 209539-06-0P 209539-08-2P
209539-09-3P 209539-10-6P 209539-11-7P 209539-12-8P
209539-13-9P 209539-15-1P 209539-16-2P 209539-17-3P
209539-18-4P 209539-19-5P 209539-20-8P 209539-22-0P
209539-24-2P 209539-25-3P 209539-26-4P 209539-27-5P
209539-28-6P 209539-29-7P 209539-31-1P 209539-32-2P
209539-33-3P 209539-34-4P 209539-36-6P 209539-37-7P
209539-38-8P 209539-39-9P 209539-40-2P 209539-42-4P

209539-43-5P 209539-44-6P 209539-45-7P 209539-46-8P
209539-48-0P 209539-49-1P 209539-50-4P 209539-51-5P
209539-52-6P 209539-54-8P 209539-55-9P 209539-56-0P
209539-57-1P 209539-58-2P 209539-59-3P 209539-61-7P
209539-62-8P 209539-63-9P 209539-64-0P 209539-65-1P
209539-66-2P 209539-67-3P 209539-69-5P 209539-70-8P
209539-71-9P 209539-72-0P 209539-73-1P 209539-74-2P
209539-76-4P 209539-77-5P 209539-78-6P 209539-79-7P
209539-80-0P 209539-81-1P 209539-83-3P 209539-84-4P
209539-85-5P 209539-86-6P 209539-87-7P 209539-89-9P
209539-90-2P 209539-91-3P 209539-92-4P 209539-94-6P
209539-95-7P 209539-96-8P 209539-97-9P 209539-99-1P
209540-00-1P 209540-01-2P 209540-02-3P 209540-03-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivs. as Na+/H+ exchanger inhibitors for treatment of diseases)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'MARPATPREV' ENTERED AT 12:55:12 ON 14 FEB 2003

L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 2
GGCAT IS UNS AT 5
GGCAT IS UNS AT 15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
MLEVEL IS CLASS ON RING NODES AND RING GROUPS
MLEVEL IS CLASS ON CHAIN NODES AND CHAIN GROUPS
ECLEVEL IS LIM ON ALL NODES

ALL RING(S) ARE ISOLATED

L9 0 SEA FILE=MARPATPREV SSS FUL L1 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 52 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.03

FILE 'HOME' ENTERED AT 12:55:42 ON 14 FEB 2003

(FILE 'REGISTRY' ENTERED AT 12:45:59 ON 14 FEB 2003)

L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 2
GGCAT IS UNS AT 5
GGCAT IS UNS AT 15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L3 48 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 48 ITERATIONS 48 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'HCAPLUS' ENTERED AT 12:50:37 ON 14 FEB 2003)
L4 3 S L3

=> sel hit l4 1-3 rn
E1 THROUGH E48 ASSIGNED

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:693123 HCAPLUS
DOCUMENT NUMBER: 137:210930
TITLE: Enzyme-activated cytostatic conjugates with integrin ligands
INVENTOR(S): Lerchen, Hans-georg; Baumgarten, Joerg; Schoop, Andreas; Albers, Markus
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

EP 1238678	A1	20020911	EP 2001-105350	20010308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002072151	A1	20020919	WO 2002-EP2501	20020307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002193311	A1	20021219	US 2002-96120	20020308

PRIORITY APPLN. INFO.: EP 2001-105350 A 20010308

OTHER SOURCE(S): MARPAT 137:210930

AB The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to .alpha.v.beta.3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can esp. be found in tumor tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and .alpha.v.beta.3 integrin antagonist in biol. fluids and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymic or hydrolytic cleavability with release of the cytostatic.

IT **455940-45-1P 455940-48-4P 455940-51-9P**
455940-53-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

RN 455940-45-1 HCAPLUS

CN L-Valine, N-[[[4-[[[[(1S)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]glycyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



RN 455940-48-4 HCAPLUS
CN L-Valine, N-[[[4-[[[[(1R)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]glycyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



RN 455940-51-9 HCAPLUS
CN L-Valine, N-[[[4-[[[[(1R)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-alanyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



RN 455940-53-1 HCAPLUS
CN L-Valine, N-[[[4-[[[[(1S)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-alanyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



IT **455940-58-6P 455940-60-0P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

RN 455940-58-6 HCAPLUS

CN L-Valine, N2-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-asparaginyl-L-prolyl-

, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



RN 455940-60-0 HCAPLUS
CN L-Valine, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-norvalyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-

pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



IT **455940-55-3P 455940-63-3P 455940-65-5P 455940-67-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(enzyme-activated cytostatic conjugates with integrin ligands

which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

RN 455940-55-3 HCAPLUS

CN L-Valine, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-histidyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 455940-63-3 HCAPLUS
CN L-Valine, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-.alpha.-aspartyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 455940-65-5 HCAPLUS
CN L-Leucine, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]glycyl-L-prolyl-, 3-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 455940-67-7 HCAPLUS
CN L-Leucinamide, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-alanyl-L-prolyl-N-[(3aS,4S,7aR)-2-(3-carboxy-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-2,3,3a,4,7,7a-hexahydro-1H-isoindol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





IT **330155-52-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
RN 330155-52-7 HCAPLUS
CN Benzenepropanoic acid, .beta.-[[[(4-aminophenyl)amino]carbonyl]amino]-3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:503334 HCAPLUS
DOCUMENT NUMBER: 137:63479
TITLE: Preparation of conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
INVENTOR(S): Lerchen, Hans-Georg; Baumgarten, Joerg; Lockhoff, Oswald; Albers, Markus; Schoop, Andreas
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 127 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1219305	A1	20020703	EP 2000-128401	20001227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002051444	A1	20020704	WO 2001-EP14965	20011218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002183256	A1	20021205	US 2001-26408	20011221

PRIORITY APPLN. INFO.: EP 2000-128401 A 20001227

OTHER SOURCE(S): MARPAT 137:63479

AB The invention relates to cytostatics CT-LI-Sp-IA [CT denotes a cytotoxic radical or a radical of a cytostatic or a cytostatic deriv. which can addnl. carry a hydroxy, carboxy or amino group; LI is a linker group comprising 5- to 8-amino acid residues in the D- or L-configuration, which can each optionally carry protective groups; Sp is absent or a carbonyl or thiocarbonyl radical; IA is a non-peptide radical addressing an .alpha.v.beta.3 integrin receptor, e.g., a radical of formula R18COCH2CHPhNHCOCH2NHCO-m-C6H4NH[C(:NH)NHR19]q, where R18 is OH, (un)substituted (cyclo)alkoxy, aryloxy, heterocyclyloxy, a direct bond, or an atom from the group N, O and S, via which the radical is bonded to the rest of the conjugate; q is 0 or 1; R19 is H, (un)substituted (cyclo)alkyl, aryl, heterocyclyl, an alkylamine or alkylamide radical, or a direct bond, via which the radical is bonded to the rest of the conjugate] and their physiol. acceptable salts and stereoisomers. The cytostatics have a tumor-specific action as a result of linkage to .alpha.v.beta.3integrin antagonists via preferred linking units which can be selectively cleaved by enzymes such as metallo matrix proteases (MMPs5), i.e., by enzymes which can esp. be found in tumor tissue. The preferred linking units guarantee the serum stability of the conjugate of cytostatic and .alpha.v.beta.3 integrin antagonist and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymic or hydrolytic cleavability with release of the cytostatic. Thus, 20-O-[PrNHCONH-m-C6H4SO2NH-m-C6H4CH(CH2CO2H)NHCONH-p-C6H4NHC(S)-Pro-Leu-Gly-Leu-His-Val]camptothecin (1) was prepd. by reaction of 20(S)-camptothecin with N-(tert-butoxycarbonyl)-L-valine-N-carboxyanhydride, deprotection, peptide coupling reactions, and formation of the thiourea linkage. Compd. 1 was assayed for cytostatic action on human large intestine cell line HT29 (IC50 = 40 nM).

IT **439864-66-1P 439864-67-2P 439864-68-3P**
439864-71-8P 439864-73-0P 439864-74-1P
439864-75-2P 439864-76-3P 439864-77-4P
439864-78-5P 439864-79-6P 439864-80-9P
439864-81-0P 439864-82-1P 439864-83-2P
439864-84-3P 439864-85-4P 439864-86-5P

439864-87-6P 439864-88-7P 439864-89-8P
439864-90-1P 439864-91-2P 439864-92-3P
439864-93-4P 439864-94-5P 439864-95-6P
439864-96-7P 439864-97-8P 439864-98-9P
439864-99-0P 439865-00-6P 439865-01-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units)

RN 439864-66-1 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-67-2 HCAPLUS
CN L-Valine, 1-[[[4-[[[[(1R)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-68-3 HCAPLUS
CN L-Valine, 1-[[[4-[[[[(1S)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-71-8 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-73-0 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-, 5-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-74-1 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-75-2 HCAPLUS
CN L-Valine, 1-[[[4-[[[[(1R)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-76-3 HCAPLUS
CN L-Valine, 1-[[[4-[[[[(1S)-2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-77-4 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-78-5 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-S-methyl-L-cysteinyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-79-6 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-80-9 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-81-0 HCAPLUS
CN L-Valine, 1-[4-[[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]amino]-1-oxobutyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-82-1 HCAPLUS
CN L-Valine, 1-[4-[[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]amino]-1-oxobutyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-83-2 HCAPLUS
CN L-Valine, 1-[4-[[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]amino]-1-oxobutyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-84-3 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-S-methyl-L-cysteinyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-85-4 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-lysyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-86-5 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl}amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-norvalyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-87-6 HCAPLUS
CN L-Valine, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]glycyl-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 7-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-88-7 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolylglycylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-89-8 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-histidylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-90-1 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-histidyl-, 5-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-91-2 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 7-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-92-3 HCAPLUS
CN L-Valine, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]glycyl-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 7-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-93-4 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-alanyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-94-5 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-D-alanyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-95-6 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-valyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-96-7 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-phenylalanyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-97-8 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-seryl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-98-9 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-isoleucyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439864-99-0 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-.alpha.-glutamyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439865-00-6 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucylglycyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 439865-01-7 HCAPLUS
CN L-Valine, 1-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-prolyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT **330155-52-7P 439865-61-9P 439865-65-3P**
439865-66-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT (Reactant or reagent)
(prepn. of conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units)

RN 330155-52-7 HCAPLUS
CN Benzenepropanoic acid, .beta.-[[[(4-aminophenyl)amino]carbonyl]amino]-3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 439865-61-9 HCAPLUS
CN Benzenepropanoic acid, .beta.-[[[(4-nitrophenyl)amino]carbonyl]amino]-3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 439865-65-3 HCAPLUS
CN Benzenepropanoic acid, .beta.-[[[(4-aminophenyl)amino]carbonyl]amino]-3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]-, (.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439865-66-4 HCAPLUS
CN Benzenepropanoic acid, .beta.-[[[(4-aminophenyl)amino]carbonyl]amino]-3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:185604 HCAPLUS
DOCUMENT NUMBER: 134:237346
TITLE: Preparation of peptidyl camptothecin conjugates as antitumor agents
INVENTOR(S): Lerchen, Hans-Georg; Baumgarten, Joerg; Brueggemeier, Ulf; Albers, Markus; Schoop, Andreas; Schulze, Thomas
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017563	A2	20010315	WO 2000-EP8361	20000828
WO 2001017563	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013883	A	20020507	BR 2000-13883	20000828
EP 1235595	A2	20020904	EP 2000-965901	20000828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-392167 A 19990908
US 2000-606772 A 20000629
WO 2000-EP8361 W 20000828

OTHER SOURCE(S): MARPAT 134:237346
GI



AB Title compds., e.g., I, cytostatics which have a tumor-specific action as a result of linkage to .alpha.V.beta.3 integrin ligands, were prepd.. Data for biol. activity of title compds. were given.

IT **330155-15-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptidyl camptothecin conjugates as antitumor agents)

RN 330155-15-2 HCAPLUS

CN L-Valine, N-[[[4-[[[[2-carboxy-1-[3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-histidyl-, 2-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **330155-52-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of peptidyl camptothecin conjugates as antitumor agents)
RN 330155-52-7 HCAPLUS
CN Benzenepropanoic acid, .beta.-[[[(4-aminophenyl)amino]carbonyl]amino]-3-[[[3-[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



FILE 'CAOLD' ENTERED AT 12:51:17 ON 14 FEB 2003
L5 0 S L3

FILE 'USPATFULL' ENTERED AT 12:51:23 ON 14 FEB 2003
L6 2 S L3

L6 ANSWER 1 OF 2 USPATFULL
ACCESSION NUMBER: 2002:337946 USPATFULL
TITLE: Novel cytostatic conjugates with integrin ligands
INVENTOR(S): Lerchen, Hans-Georg, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schoop, Andreas, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Albers, Markus, Leverkusen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002193311	A1	20021219	
APPLICATION INFO.:	US 2002-96120	A1	20020308	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2001-105350	20010308

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jeffrey M. Greenman, Vice President, Patents and Licensing, Bayer Corporation, 400 Morgan Lane, West Haven, CT, 06516
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 2658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to .alpha..sub.v.beta..sub.3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and .alpha..sub.v.beta..sub.3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPATFULL
ACCESSION NUMBER: 2002:323090 USPATFULL

TITLE: Cytostatic-integrin conjugates having specifically cleavable linking units

INVENTOR(S): Lerchen, Hans-Georg, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lockhoff, Oswald, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Albers, Markus, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Schoop, Andreas, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002183256	A1	20021205	
APPLICATION INFO.:	US 2001-26408	A1	20011221	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-128401	20001227

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jeffrey M. Greenman, Vice President, Patents and Licensing, Bayer Corporation, 400 Morgan Lane, West Haven, CT, 06516
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 5098

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to .alpha..sub.v.beta..sub.3 integrin antagonists via preferred linking units which can be selevtively cleaved by enzymes such as metallo matrixproteases (MMPs), i.e. by enzymes which can especially be found in tumor tissue. The preferred linking units guarantee the serum stability of the conjugate of cytostatic and .alpha..sub.v.beta..sub.3 integrin antagonist and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'MARPAT' ENTERED AT 12:51:41 ON 14 FEB 2003)
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 2
GGCAT IS UNS AT 5
GGCAT IS UNS AT 15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
MLEVEL IS CLASS ON RING NODES AND RING GROUPS
MLEVEL IS CLASS ON CHAIN NODES AND CHAIN GROUPS
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L8 5 SEA FILE=MARPAT SSS FUL L1 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 14824 ITERATIONS (2 INCOMPLETE) 5 ANSWERS
SEARCH TIME: 00.01.12

L8 ANSWER 1 OF 5 MARPAT COPYRIGHT 2003 ACS
ACCESSION NUMBER: 137:210930 MARPAT
TITLE: Enzyme-activated cytostatic conjugates with integrin ligands
INVENTOR(S): Lerchen, Hans-georg; Baumgarten, Joerg; Schoop, Andreas; Albers, Markus
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 1238678 A1 20020911 EP 2001-105350 20010308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
WO 2002072151 A1 20020919 WO 2002-EP2501 20020307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002193311 A1 20021219 US 2002-96120 20020308
PRIORITY APPLN. INFO.: EP 2001-105350 20010308

AB The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to .alpha.v.beta.3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can esp. be found in tumor tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and .alpha.v.beta.3 integrin antagonist in biol. fluids and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymic or hydrolytic cleavability with release of the cytostatic.

IC ICM A61K047-48
CC 1-6 (Pharmacology)
Section cross-reference(s): 25, 28, 34, 63
ST enzyme activated cytostatic conjugate integrin ligand
IT Antitumor agents
(carcinoma; enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
IT Cytotoxic agents
Human
Solid phase synthesis
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
IT Toxicity
(hemotoxicity; enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
IT Carcinoma
(inhibitors; enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
IT Drug delivery systems
(prodrugs; enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
IT Hematopoietic precursor cell
(stem, toxicity to; enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.3; enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 455940-45-1P 455940-48-4P 455940-51-9P 455940-53-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 9004-06-2, Elastase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 7689-03-4, 20(S)-Camptothecin
RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 455940-58-6P 455940-60-0P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 455940-55-3P 455940-63-3P 455940-65-5P 455940-67-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 7689-03-4D, Camptothecin, conjugates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 67-63-0, 2-Propanol, reactions 99-61-6, 3-Nitrobenzaldehyde 100-28-7, 4-Nitrophenyl isocyanate 107-10-8, Propylamine, reactions 110-78-1, Propyl isocyanate 121-51-7, 3-Nitrobenzenesulfonyl chloride 2937-50-0, Allyloxycarbonyl chloride 3392-05-0 3392-12-9 4125-93-3 13139-15-6, N-(tert-Butoxycarbonyl)leucine 205687-19-0 282525-10-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)

IT 283613-06-9P 283613-07-0P 330155-29-8P 330155-52-7P
330155-53-8P 455940-71-3P 455940-75-7P 455940-80-4P
455940-83-7P 455940-86-0P 455940-90-6P 455940-94-0P
455940-98-4P 455941-04-5P 455941-07-8P 455941-11-4P
455941-15-8P 455941-17-0P 455941-19-2P 455941-21-6P

455941-23-8P 455941-25-0P 455941-26-1P 455941-27-2P
455941-28-3P 455941-29-4P 455941-30-7P 455941-31-8P
455941-32-9P 455941-33-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enzyme-activated cytostatic conjugates with integrin ligands which can be selectively cleaved by elastase in relation to toxicity to hemopoietic stem cells)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 5 MARPAT COPYRIGHT 2003 ACS
ACCESSION NUMBER: 134:237346 MARPAT
TITLE: Preparation of peptidyl camptothecin conjugates as antitumor agents
INVENTOR(S): Lerchen, Hans-Georg; Baumgarten, Joerg; Brueggemeier, Ulf; Albers, Markus; Schoop, Andreas; Schulze, Thomas
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017563	A2	20010315	WO 2000-EP8361	20000828
WO 2001017563	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013883	A	20020507	BR 2000-13883	20000828
EP 1235595	A2	20020904	EP 2000-965901	20000828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-392167 19990908
US 2000-606772 20000629
WO 2000-EP8361 20000828

GI



AB Title compds., e.g., I, cytostatics which have a tumor-specific action as a result of linkage to .alpha.V.beta.3 integrin ligands, were prepd.. Data for biol. activity of title compds. were given.

IC ICM A61K047-48

CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 34

ST peptidyl camptothecin conjugate prepn antitumor agent

IT Antitumor agents
(peptidyl camptothecin conjugates)

IT Integrins
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(.alpha.v.beta.3; prepn. of peptidyl camptothecin conjugates as antitumor agents)

IT Integrins
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(.alpha.v.beta.5; prepn. of peptidyl camptothecin conjugates as antitumor agents)

IT 330154-85-3P 330154-86-4P 330154-87-5P 330154-88-6P
330154-89-7P 330154-90-0P 330154-91-1P 330154-92-2P
330154-93-3P 330154-94-4P 330154-95-5P 330154-96-6P
330154-97-7P 330154-98-8P 330154-99-9P 330155-00-5P
330155-01-6P 330155-02-7P 330155-03-8P 330155-04-9P
330155-06-1P 330155-08-3P 330155-09-4P 330155-10-7P
330155-11-8P 330155-12-9P 330155-13-0P 330155-14-1P
330155-15-2P 330155-16-3P 330155-17-4P 330155-18-5P
330155-20-9P 330155-22-1P 330155-24-3P 330155-25-4P
330155-26-5P 330155-27-6P 330155-28-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptidyl camptothecin conjugates as antitumor agents)

IT 98-09-9, Benzenesulfonyl chloride 98-58-8, 4-Bromobenzenesulfonyl chloride 98-74-8, p-Nitrobenzenesulfonyl chloride 99-61-6,

3-Nitrobenzaldehyde 100-28-7, 4-Nitrophenyl isocyanate 100-52-7, Benzaldehyde, reactions 103-72-0, Phenyl isothiocyanate 107-10-8, Propylamine, reactions 108-30-5, Succinic anhydride, reactions 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-90-4, 3-Nitrobenzoyl chloride 141-82-2, Malonic acid, reactions 150-13-0, p-Aminobenzoic acid 934-32-7, 2-Aminobenzimidazole 2905-24-0, 3-Bromobenzenesulfonyl chloride 2937-50-0, Allyl chloroformate 3392-07-2 7689-03-4, (S)-Camptothecin 13030-09-6 13331-27-6, 3-Nitrophenylboronic acid 21286-54-4, (1S)-10-Camphorsulfonyl chloride 23095-05-8, 5-Bromo-2-methoxybenzenesulfonyl chloride 30418-59-8, 3-Aminophenylboronic acid 91421-43-1, 9-Aminocamptothecin 95753-55-2 141468-55-5 180181-93-5 269078-76-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of peptidyl camptothecin conjugates as antitumor agents)

IT 150-30-1P, Phenylalanine 6335-76-8P, Ethyl 3-amino-3-phenylpropionate 188803-59-0P 188803-62-5P 188805-48-3P
188812-76-2P 188815-24-9P 205687-80-5P 205687-87-2P
205688-17-1P 276260-09-4P 276260-12-9P 276260-17-4P
282525-10-4P 283613-06-9P 283613-07-0P 283613-08-1P
283613-09-2P 283613-10-5P 283613-11-6P 283613-55-8P
283613-56-9P 283613-57-0P 283613-58-1P 283613-59-2P
283613-60-5P 288389-44-6P 330155-29-8P 330155-31-2P
330155-32-3P 330155-33-4P 330155-34-5P 330155-35-6P
330155-36-7P 330155-37-8P 330155-38-9P 330155-39-0P
330155-40-3P 330155-41-4P 330155-43-6P 330155-44-7P
330155-45-8P 330155-46-9P 330155-48-1P 330155-49-2P
330155-50-5P 330155-51-6P 330155-52-7P 330155-53-8P
330155-54-9P 330155-55-0P 330155-56-1P 330155-57-2P
330155-58-3P 330155-59-4P 330155-61-8P 330155-62-9P
330155-63-0P 330155-64-1P 330155-65-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of peptidyl camptothecin conjugates as antitumor agents)

L8 ANSWER 3 OF 5 MARPAT COPYRIGHT 2003 ACS
ACCESSION NUMBER: 133:105343 MARPAT
TITLE: Preparation of .beta.-phenylalanine derivatives as integrin antagonists
INVENTOR(S): Schoop, Andreas; Muller, Gerhard; Bruggemeier, Ulf; Schmidt, Delf; Stelte-Ludwig, Beatrix; Keldenich, Jorg; Albers, Markus
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041469	A2	20000720	WO 2000-EP120	20000111
WO 2000041469	A3	20001116		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6291503	B1	20010918	US 1999-232738	19990115
CA 2360356	AA	20000720	CA 2000-2360356	20000111
EP 1147079	A2	20011024	EP 2000-903571	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534439	T2	20021015	JP 2000-593094	20000111
US 2001031788	A1	20011018	US 2001-867835	20010530
PRIORITY APPLN. INFO.:			US 1999-232738	19990115
			WO 2000-EP120	20000111

GI

I

AB .beta.-Phenylalanine derivs. I [R1 = H, (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl; R2, R3 = any group given for R1 or (un)substituted alkenyl or alkynyl, OH, alkoxy or R2 and R3 are bonded to each other; R4 = carboxy ester, SO2H, CHO, CONH2, C(S)NH2 or their derivs.; R5 = H, (un)substituted alkyl, cycloalkyl, aryl; R6 = any group given for R1 or is bonded to one of R7, R8 or R9; R7 is absent, H, (un)substituted alkyl or cycloalkyl, NO2, CN, CHO or CO2H or their derivs., or is bonded to one of R6, R8, or R9; R8, R9 = any group given for R1 or is bonded to one of R6, R7 or R9 or R8; R10, R11 = H, (un)substituted alkyl, cycloalkyl, or alkoxy, halo; L is a sulfonamide, amide, ether, ester, keto, urea, thioether, sulfoxide or sulfone unit optionally extended by one or two methylene groups; X is N, O or S] and their physiol. acceptable salts and stereoisomers were prepd. Thus, 3-[(phenylsulfonyl)amino]-3-[3-[(3-guanidinophenyl)sulfonyl]phenyl]propionic acid trifluoroacetic acid salt, prepd. by a multistep procedure from 3-nitrobenzaldehyde, ammonium acetate, malonic acid, benzenesulfonyl chloride, 3-nitrobenzenesulfonyl chloride, and 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, showed IC50 = 19 nM antagonist activity against integrin .alpha.v.beta.3 receptor.

IC C07D401-00

CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

ST phenylalanine beta deriv prepn integrin antagonist

IT Angiogenesis
Antitumor agents
Arteriosclerosis
Eye, disease
Osteoporosis
Rheumatoid arthritis